Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CBX7 | O95931 | 2/20 | 0.44 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.44 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282822 | 0.82 | BCHE (0.49) | BCHECBX7CDY1; CDY1BCDYLCNR2 | |
| SCHEMBL6285224 | 0.78 | ALDH1A1 (0.47) | BCHECBX7CDY1; CDY1BCNR2CNR1 | |
| SCHEMBL6284061 | 0.77 | BCHE (0.47) | BCHECBX7CDY1; CDY1BNR4A1NR4A2 | |
| SCHEMBL6278888 | 0.76 | TACR1 (0.48) | BCHECBX7CDY1; CDY1BCDYLCNR2 | |
| SCHEMBL11575158 | 0.72 | BCHE (0.56) | BCHECNR2NR4A1NR4A2NR4A3 | |
| SCHEMBL6284085 | 0.71 | BCHE (0.49) | BCHECBX7CDY1; CDY1BCDYLCNR2 | |
| SCHEMBL6287272 | 0.70 | ELANE (0.49) | BCHECBX7CDY1; CDY1BCDYLELANE | |
| SCHEMBL31047678 | 0.69 | BCHE (0.56) | BCHECNR2NR4A1NR4A2NR4A3 | |
| SCHEMBL28265974 | 0.69 | BCHE (0.52) | BCHECNR2CNR1NR4A1NR4A2 | |
| SCHEMBL6278686 | 0.68 | BCHE (0.43) | BCHECBX7CDY1; CDY1BCDYLNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919365-B2 | Imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1384715-A1 | NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | CMA1, TPSD1, TPSB2 | BCHE 515/4885CBX7 2579/4885CDY1; CDY1B 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.